Intervention not reported
Bleeding complications · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in bleeding complications (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (sensitivity analysis unpublished) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (sensitivity analysis unpublished) (moderate certainty).
1 finding from 1 review
All‐cause mortality (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
COPD exacerbations · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler probably leads to lower acute exacerbations of COPD (4‐week to 24‐week compared with placebo (moderate certainty).
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · Adults with COPD
1 finding from 1 review
FEV1 · Adults with COPD
1 finding from 1 review
Difference vs placebo in adjusted peak FEV1 (3‐week to 6‐month · Adults with COPD
1 finding from 1 review
Adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 5‐ to 6‐year · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 12 year · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 2 year · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: chemotherapy Outcome: neurocognitive impairment at 3 year · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: radiotherapy Comparison: chemotherapy Outcome:… (low certainty).
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 2 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: chemoradiotherapy Comparison: radiotherapy Outcome: neurocognitive impairment at 3 years after treatment · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: chemoradiotherapy Comparison: radiotherapy Outcome:… (low certainty).
1 finding from 1 review
Intervention not reported
Intervention: stereotactic conformal radiotherapy Comparison: radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: stereotactic conformal radiotherapy Comparison:… (low certainty).
1 finding from 1 review